Compare Unity Software Inc (U) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unity Software Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Unity Software Inc trades at $46.71 (market cap $20.20B), while State Street SPDR S&P Biotech ETF trades at $154.31 (market cap $10.11B). The key difference: Unity Software Inc is the larger of the two by market cap, and Unity Software Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Unity Software Inc for 50 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| U | XBI | |
|---|---|---|
Market Cap | $20.20B | $10.11B |
Volume | 15,432,191 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $49.47 | $169.55 |
52-Week Low | $17.13 | $104.99 |
Typical Hold Time | 50 Days | 37 Days |
Enterprise Value | $20.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unity Software (U) trades at $46.77, up 2.93% with strong bullish momentum. The stock shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though still unprofitable. Technical indicators signal bullish sentiment with the current price near resistance at $47. Recent news highlights Meta VR partnership driving positive sentiment, while analyst consensus remains strongly bullish with 82.76% buy ratings.
Unity presents a growth opportunity with strategic partnerships and improving financial trends, but faces significant execution risks. The company's high valuation multiples and persistent losses require careful monitoring of profitability progress. Near-term catalysts include VR market expansion and advertising platform growth, though competitive pressures and macroeconomic uncertainty remain key concerns.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
